Phase II Open‐Label Study of Anakinra in Intravenous Immunoglobulin–Resistant Kawasaki Disease

Study in 16 patients with Kawasaki disease not responsive to 1 or more courses of 2 mg/kg of intravenous immunoglobulin found anakinra (starting dose 2 mg/kg titrated to 6 mg/kg per 24 hours) reduced disease activity by 50% on 93.3% of physician evaluations.

Source:

Arthritis & Rheumatology